Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05641935 · ClinicalTrials.gov registry record · Phase 2
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
A Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, sponsored by john eisenbrey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 1
- Study location
NCT05641935: Recruiting Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, sponsored by john eisenbrey.
NCT05641935 is a Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma that is actively recruiting participants, run by john eisenbrey. The registered enrollment target is 210 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05641935, a Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, is actively recruiting participants, sponsored by john eisenbrey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Primary Outcome
Baseline imaging will be reviewed and compared to the contrast enhanced imaging to diagnose recurrence.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- OTHER Electronic Health Record Review
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Sulfur Hexafluoride Lipid Microspheres
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
What NCT05641935 shows while recruiting
NCT05641935 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% lower).
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05641935 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05641935 about?
NCT05641935 is a clinical study titled "Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation". This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or m...
What is the current status of trial NCT05641935?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2022-11-03. Estimated completion is 2027-08-31.
What conditions does trial NCT05641935 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma.
What interventions are being tested in trial NCT05641935?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Electronic Health Record Review (OTHER), Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG).
Who is sponsoring clinical trial NCT05641935?
This trial is sponsored by john eisenbrey, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05641935 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05641935's enrollment target sits among peer trials
210 29th of 121 higher than 93 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI